Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Short Interest Update

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) saw a significant decrease in short interest in July. As of July 31st, there was short interest totalling 6,220,000 shares, a decrease of 10.1% from the July 15th total of 6,920,000 shares. Based on an average daily volume of 544,200 shares, the short-interest ratio is presently 11.4 days. Approximately 19.6% of the company’s shares are sold short.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock traded down $0.22 during mid-day trading on Friday, reaching $35.26. The company had a trading volume of 206,394 shares, compared to its average volume of 468,546. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. Collegium Pharmaceutical has a 52 week low of $20.95 and a 52 week high of $40.95. The company has a 50 day moving average of $33.44 and a 200-day moving average of $34.91. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of 14.69 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.22. The firm had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.13 EPS. On average, sell-side analysts expect that Collegium Pharmaceutical will post 5.73 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Colleen Tupper sold 19,710 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the sale, the chief financial officer now owns 130,845 shares of the company’s stock, valued at $4,476,207.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $33.98, for a total value of $1,930,301.86. Following the completion of the transaction, the executive vice president now directly owns 105,902 shares of the company’s stock, valued at $3,598,549.96. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the transaction, the chief financial officer now directly owns 130,845 shares of the company’s stock, valued at $4,476,207.45. The disclosure for this sale can be found here. 3.98% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Gladius Capital Management LP acquired a new position in Collegium Pharmaceutical in the 2nd quarter valued at about $32,000. Principal Securities Inc. acquired a new position in Collegium Pharmaceutical in the 4th quarter valued at about $40,000. nVerses Capital LLC grew its stake in Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,600 shares during the last quarter. Assetmark Inc. grew its stake in Collegium Pharmaceutical by 25.5% in the 4th quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after buying an additional 1,108 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC bought a new stake in Collegium Pharmaceutical in the 1st quarter valued at about $204,000.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on COLL. Truist Financial lifted their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the company from $41.00 to $44.00 in a research report on Friday, June 7th. StockNews.com raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 12th. Piper Sandler reissued a “neutral” rating and set a $37.00 target price (down from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, HC Wainwright raised shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday, July 30th. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $42.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.